No profile data available.
Trevena, Inc. (TRVN) is a healthcare company in the opioid pain relief pharmaceuticals industry, based in Chesterbrook, United States, with about 23 full-time employees.
It reported revenue of $3.13 million for fiscal year 2023, and net income of -$40.29 million. In Q3 2024 (the quarter ended September 30, 2024) revenue was $283,000, up 57.2% from a year before. Its market capitalization was $10,365 as of October 8, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2023; market data as of October 8, 2026.
, a biopharmaceutical company, focuses on the development and commercialization of novel medicines for patients affected by central nervous system disorders.
Trevena reported $3.13 million in revenue for fiscal year 2023. In Q3 2024 revenue was $283,000.
$10,365 as of October 8, 2026.
Listed companies of a similar size in the same industry (opioid pain relief pharmaceuticals) include Collegium Pharmaceutical, Inc. (COLL), Ensysce Biosciences, Inc. (ENSC), Avenue Therapeutics, Inc. (ATXI).